Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 293.00
Bid: 290.00
Ask: 293.00
Change: -3.00 (-1.01%)
Spread: 3.00 (1.034%)
Open: 286.00
High: 293.00
Low: 284.00
Prev. Close: 296.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Hutchmed up on positive results for cancer drug

Mon, 14th Nov 2022 10:27

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Hutchmed (China) Ltd, up 13% at 184.96 pence, 12-month range 1.30p - 194.00p. The Hong Kong-based biopharmaceutical company reports positive top-line results for its gastric cancer treatment fruquintinib, when combined with paclitaxel. The drug met one of its primary endpoints of statistically significant improvement in progression-free survival during a phase three study in 703 patients, which the firm explains is clinically meaningful. The study looked at patients with advanced gastric or gastroesophageal junction adenocarcinoma, a type of cancer.

----------

Midatech Pharma PLC, up 7.2% at 6.49 pence, 12-month range 6.00p - 24.63p. Enrols the first patient into its phase one study of MTX-110 in recurrent glioblastoma, a type of cancer that appears in the brain or spinal cord. The study is an open-label, dose escalation study to assess the feasibility and safety of intermittent infusions of MTX-100. Cardiff-based biotechnology firm Midatech says it previously reported "encouraging results" from a phase one study of MTX-110 in diffuse intrinsic pontine glioma, a type of tumour that is located on the brain stem.

----------

SRT Marine Systems PLC, up 7.6% at 48.95 pence, 12-month range 23.60p - 55.00p. The maritime surveillance, analytics and management systems developer reports a steep increase in interim revenue as it swings to a pretax profit of GBP2.1 million from a loss of GBP3.1 million. In the six months to September 30, SRT Marine Systems reports revenue of GBP18.8 million, multiplied from GBP4.7 million the previous year. This, it adds, is despite ongoing component supply issues. Chief Executive Simon Tuckers expects this strong performance to continue going forward as long-term demand stays robust.

----------

AIM - LOSERS

----------

Tremor International Ltd, down 26% at 281.00 pence, 12-month range 2.90p - 330.60p. Swings to a total comprehensive IFRS loss of USD5.2 million in the three months ended September 30, from a profit of USD10.2 million the previous year. Revenue in the quarter drops 19% year-on-year to USD70.9 million from USD87.0 million. Despite the drop in profit and revenue, Tremor says it remains "well-positioned" to benefit from "anticipated industry secular growth trends" which it expects to help mitigate potential negative effects. Full-year adjusted earnings before interest, taxation, depreciation, and amortization is expected at USD140 million.

----------

Shanta Gold Ltd, down 12% at 9.60 pence, 12-month range 6.50p - 14.00p. Three companies which previously expressed interest in the East Africa-focused gold producer, developer and explorer say they do not intend to make an offer for the firm. In October, Shanta received approaches from Shandong Gold Group Co Ltd, Yintai Gold Co Ltd and Chaarat Gold Holdings Ltd. These companies have since decided not to proceed with an offer. Nonetheless, Shanta says it continues to believe in the strength of its business and the potential of its portfolio.

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
17 Apr 2019 16:02

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 18 AprilDomino's Pizza GroupSEGRORPC Group (re acquisition by Berry 19 events 22 events 23

Read more
3 Apr 2019 12:58

Gama Aviation Appoints Managing Director Of Major Shareholder As Chair

LONDON (Alliance News) - Gama Aviation PLC on Wednesday said it has selected the managing director of major shareholder Hutchison Whampoa China Ltd as its new chair.Shares in business firm

Read more
29 Mar 2019 09:16

Hutchison China MediTech Surufatinib Cancer Study Doses First Patient

LONDON (Alliance News) - Biopharmaceutical firm Hutchison China MediTech Ltd on Friday said it has begun a study of cancer drug surufatinib in patients with advanced biliary tract biliary tract by

Read more
11 Mar 2019 11:54

Hutchison loss widens as China legislation hampers revenue

(Sharecast News) - Hutchison China Meditech on Monday reported a drop in sales and increased annual loss after the implementation of new government policy in China.

Read more
11 Mar 2019 08:45

Hutchison China Meditech 2018 Loss Widens On New Government Policy

LONDON (Alliance News) - Hutchison China Meditech Ltd on Monday said its loss widened in 2018 as sales decreased following an implementation of new government policy in China.The company to

Read more
29 Nov 2018 12:17

Hutchison Chi-Med enters four new drug test collaborations

(Sharecast News) - Hutchison China MediTech, doing business as Chi-Med, has entered into four collaboration agreements to evaluate the safety, tolerability and efficacy of its 'surufatinib' (HMPL-012 or sulfatinib) and 'fruquintinib' products, in combination with checkpoint inhibitors.

Read more
26 Nov 2018 08:35

Hutchison China Meditech Starts Fruquintinib Capsules Sales In China

LONDON (Alliance News) - Hutchison China Meditech Ltd on Monday said it launched fruquintinib capsules Elunate with the initiation of product sales in China.Elunate is used for the of with

Read more
19 Nov 2018 19:02

SVM UK Emerging Fund Beats Benchmark With Three Key Holdings

LONDON (Alliance News) - SVM UK Emerging Fund PLC on Monday said it had outpaced its benchmark in its most recent half year due to strong performances from three key holdings.As at 30, the

Read more
18 Oct 2018 10:09

Hutchison China Meditech Starts Phase I Study For Leukemia In China

LONDON (Alliance News) - Hutchison China Meditech Ltd said Thursday it commenced a phase I study of HMPL-523 to treat elderly patients with acute myeloid leukemia in China.The aim of the is

Read more
5 Sep 2018 08:28

Hutchison Gains Fruquintinib Capsules Approval As Cancer Drug In China

LONDON (Alliance News) - Hutchison China Meditech Ltd said Wednesday it gained Chinese approval for its Fruquintinib capsules to be used as treatment for metastatic colorectal cancer.The of

Read more
27 Jul 2018 08:54

Hutchinson China Meditech Swings To Net Loss, Ups Annual Loss Estimate

LONDON (Alliance News) - Hutchison China Meditech Ltd on Friday raised its annual loss estimate by USD20 million after swinging to an interim net loss.For the six months to June 30, the a a

Read more
20 Jul 2018 15:50

UK Earnings, Trading Statements Calendar - Next 7 Days

Monday 23 July Ryanair HoldingsQ1 ResultsAscentialHalf Year Retail GroupHalf 24

Read more
4 Jun 2018 11:11

Hutchison China Cancer Trial Shows Clinically Meaningful Benefits

LONDON (Alliance News) - Biopharmaceutical company Hutchison China MediTech Ltd said Monday patients in its FRESCO Phase III study "demonstrated a statistically significant and clinically at

Read more
20 Apr 2018 15:00

UK Shareholder Meetings Calendar - Next 7 Days

Monday 23 AprilForeign & Colonial Investment Trust BioquellMicrogenHgCapital

Read more
12 Mar 2018 08:53

Hutchison China Meditech 2017 Loss Widens Amid Rising Research Costs

LONDON (Alliance News) - China-focused drug developer and distributor Hutchison China Meditech PLC said Monday annual losses widened due to increased and

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.